Traditional methods for determining binding sites and affinities typically require the purification of recombinant proteins, which can be both time-consuming and labor-intensive. In addition ...

Domain Therapeutics (“Domain” or “the Company”), the GPCR experts harnessing deep receptor biology to develop breakthrough treatments for patients, today announces it has nominated and is progressing ...